Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Ultragenyx Pharmaceutical Inc. (RARE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update Second quarter 2023 total revenue of $108.3 million, Crysvita® revenue of $83.0 million and Dojolvi® revenue of $16.5 million Total revenue grew 21% and total Crysvita revenue grew 20% versus the second quarter 2022 Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million NOVATO, Calif. – Aug 03, 2023 – Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter ended June 30, 2023 and provided its financial guidance fo..."
07/12/2023 8-K Quarterly results
07/06/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab for the Treatment of Osteogenesis Imperfecta Pivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatric and young adult patients Newly initiated Phase 3 Cosmic study now enrolling approximately 65 younger pediatric patients"
05/17/2023 8-K Other Events  Interactive Data
05/04/2023 8-K Quarterly results
03/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/14/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/06/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones Preliminary 2022 Total Product Revenue of $352 million to $356 million, Crysvita® Revenue in Ultragenyx Territories1 of $257 million to $258 million and Dojolvi® revenue of $55 million to $56 million 2023 expected Total Product Revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million Year-end 2022 cash balance of approximately $900 million and 2023 guidance for net cash used in operations expected to be less than $400 million"
11/10/2022 8-K Quarterly results
11/02/2022 8-K Quarterly results
10/28/2022 8-K Quarterly results
09/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/28/2022 8-K Quarterly results
07/18/2022 8-K Quarterly results
07/14/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/22/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/10/2022 8-K Quarterly results
Docs: "Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update 2021 total revenue of $351.4 million and 2021 Crysvita® revenue in Ultragenyx territories1 of $192.6 million 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million Strong Dojolvi® launch continues with approximately 270 patients on reimbursed commercial therapy in the United States as of the end of 2021 Year-end 2021 cash balance of approximately $1.0 billion"
01/10/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "ULTRAGENYX REPORTS PRELIMINARY 2021 REVENUE AND 2022 REVENUE GUIDANCE FOR CRYSVITA® IN ULTRAGENYX TERRITORIES* AND DOJOLVI® GLOBALLY; PROVIDES PIPELINE UPDATES AND 2022 MILESTONES Preliminary 2021 Crysvita revenue in Ultragenyx territories of $191 million to $193 million and Dojolvi revenue of $38 million to $40 million 2022 Crysvita revenue in Ultragenyx territories expected in the range of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million Year-end 2021 cash balance of approximately $1.0 billion NOVATO, Calif — January 10, 2022 — Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today reported preliminary unaudited 2021 Crysvita® reve..."
01/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® Outside the United States Evkeeza is a first-in-class medicine approved by the U.S. Food and Drug Administration and European Commission to treat an ultra-rare inherited form of high cholesterol TARRYTOWN, N.Y. and NOVATO, C.A., January 7, 2022 –"
11/02/2021 8-K Quarterly results
Docs: "Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update Third quarter 2021 total revenue of $81.6 million including Crysvita1 revenue to Ultragenyx of $50.3 million 2021 Crysvita revenue in Ultragenyx territories1 now expected towards the upper end of the$180 million to $190 million range previously provided"
10/07/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "GeneTx and Ultragenyx Announce First Patient Dosed in Canada in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome SARASOTA, Fla., and NOVATO, Calif. — October 7, 2021"
09/27/2021 8-K Quarterly results
08/02/2021 8-K Quarterly results
06/30/2021 8-K Quarterly results
06/25/2021 8-K Quarterly results
06/10/2021 8-K Quarterly results
05/19/2021 8-K Quarterly results
05/14/2021 8-K Quarterly results
05/07/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
04/16/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy